Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEQUEL: Keytruda with Ramucirumab and Paclitaxel in Advanced Gastric and GEJ Adenocarcinoma
NCT04069273Phase 2Active, not recruiting
- Start
- Dec 2020
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma. Started Dec 2020; status: active, not recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04069273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04069273.